NSE · Healthcare · Drug Manufacturers - Specialty & Generic
EPS came in at 25.14 against a street estimate of 24.54 — a beat of 2.4%.
with an average price target of ₹2,446.14.
| Holder | Stake |
|---|---|
| HDFC Mutual Fund-HDFC Arbitrage Fund | 4.68% |
| LICI New Pension Plus Growth Fund | 3.90% |
| NPS Trust- A/C ICICI Pension Fund Scheme E - Tier I | 2.63% |
| Nippon Life India Trustee Ltd- A/C Nippon India Growth Mid Cap Fund | 2.33% |
| Mirae Asset BSE LARGEMID (60:40) Stable Dividend 50 ETF | 1.88% |
| Document | Date |
|---|---|
| Q1 FY27 earnings call LUPIN LIMITED Q1 FY2027 EARNINGS SUMMARY HEADLINE NUMBERS • Total revenues from operations: INR 8,277 crores, up 32% YoY (record high, exceeding INR | 2026-08-12 |
| Investor presentation · Q1 FY27 LUPIN LIMITED – Q1 FY27 INVESTOR SUMMARY HEADLINE NUMBERS • Net Sales: INR 82,172 mn, up 33% YoY (from INR 61,638 mn in Q1 FY26) • EBITDA: INR 24,63 | 2026-08-07 |
| Quarterly results · Q1 FY27 LUPIN LIMITED - Q1 FY2027 FINANCIAL SUMMARY HEADLINE NUMBERS • Standalone Q1 FY2027 (Quarter ended June 30, 2026): - Revenue from operations: ₹71, | 2026-08-06 |
| Investor presentation | 2026-08-06 |
| Annual report FY2026 LUPIN LIMITED – DOCUMENT SUMMARY HEADLINE NUMBERS • Final dividend declared: ₹18/- per equity share (face value ₹2/-) for financial year ended March | 2026-07-13 |
| Q4 FY26 earnings call LUPIN LIMITED – Q4 FY2026 EARNINGS SUMMARY HEADLINE NUMBERS • Total Revenue (FY26): Rs. 27,958 crores, up 23% YoY • Q4 FY26 Revenue: Rs. 7,475 crore | 2026-05-14 |
| Quarterly results · Q4 FY26 LUPIN LIMITED – FINANCIAL RESULTS SUMMARY For Year Ended March 31, 2026 --- HEADLINE NUMBERS • Full Year Revenue from Operations: ₹190,444.2 millio | 2026-05-07 |
| Investor presentation LUPIN LIMITED – Q4 FY26 INVESTOR SUMMARY HEADLINE NUMBERS • Total Sales: INR 73,919 million (Q4 FY26); INR 274,875 million (FY26) • Sales Growth: 32 | 2026-05-07 |
Readable in the app.
| Action | Detail | Date |
|---|---|---|
| Dividend | ₹18 / share ex-date Jul 17, 2026 | 2026-07-17 |
| Announcement | Date |
|---|---|
| Subsidiary enters licensing agreement, receives equity stake in U.S. biotech Lupin Limited's US subsidiary, Lupin Inc., has entered into a licensing agreement with Kaveri Therapeutics Inc. (a US company) and received 332,000 common shares as consideration. What happ | 2026-07-21 |
| Acquisition of minority shareholding in subsidiary and share buyback Lupin Limited announced two corporate actions involving its Philippine subsidiary, Multicare Pharmaceuticals Philippines, Inc. (MPPI): 1. Acquisition of Minority Shareholding: Lupin is acqu | 2026-07-01 |
| Acquisition of minority shareholding in Multicare Pharmaceuticals Philippines Lupin Limited, a major Indian pharmaceutical company, has announced an update regarding its acquisition of a minority stake in Multicare Pharmaceuticals Philippines, Inc. The announcement pr | 2026-05-29 |
| Completes acquisition of VISUfarma Lupin Limited, a major Indian pharmaceutical company, has completed its acquisition of VISUfarma. While the announcement doesn't provide specific financial details about the deal value or VI | 2026-04-02 |
| Acquisition of minority shareholding in Multicare Pharmaceuticals Philippines Lupin Limited announced that its Netherlands-based subsidiary, Nanomi B.V., has signed a definitive agreement to acquire a minority shareholding in Multicare Pharmaceuticals Philippines, Inc | 2026-04-01 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Lupin Limited — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.